PD-1、BRAF和MEK联合抑制治疗BRAFV600E结直肠癌:一项2期试验
这项单臂2期概念验证试验在37例BRAFV600E结直肠癌患者中评估PD-1抗体sparatlizumab(PDR001)、达拉非尼和曲美替尼联合治疗,主要终点总缓解率达24.3%(微卫星稳定患者25%),缓解持久性优于BRAF靶向联合治疗的历史对照。单细胞RNA测序提示MAPK抑制与肿瘤细胞内在免疫程序诱导相关。
要点
- 联合方案在BRAFV600E结直肠癌中确认缓解率24.3%,微卫星稳定患者25%。
- 缓解持久性优于BRAF靶向联合治疗的历史对照。
- 疗效较好者肿瘤细胞内在免疫程序诱导更强、MAPK抑制更完全。
核心结论
- PD-1、BRAF和MEK联合抑制在BRAFV600E结直肠癌中达到主要终点,确认缓解率及持久性优于BRAF靶向联合治疗的历史对照。
- 数据提示MAPK抑制与免疫应答之间可能存在肿瘤细胞内在协同机制,值得进一步临床评估优化的靶向与免疫联合方案。
研究设计与样本
- 概念验证单臂2期临床试验,纳入37例BRAFV600E结直肠癌患者,给予sparatlizumab(PDR001)、达拉非尼和曲美替尼联合治疗。
- 主要终点为总缓解率,次要终点为无进展生存期、疾病控制率、缓解持续时间和总生存期。
- 对23对治疗前和治疗第15天肿瘤活检进行单细胞RNA测序。
主要发现
- 确认缓解率在所有患者中为24.3%,在微卫星稳定患者中为25%。
- 缓解持久性相对BRAF靶向联合治疗单独的历史对照更有利。
- 疗效较好的患者肿瘤细胞内在免疫程序诱导更强、MAPK抑制更完全。
- 匹配的患者来源类器官中免疫程序诱导与MAPK抑制程度相关。
局限性
- 原文结论指出这些数据提示MAPK抑制与免疫应答之间可能存在肿瘤细胞内在协同机制,值得进一步临床评估优化的靶向与免疫联合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAFV600E CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone. Single-cell RNA sequencing of 23 paired pretreatment and day 15 on-treatment tumor biopsies revealed greater induction of tumor cell-intrinsic immune programs and more complete MAPK inhibition in patients with better clinical outcome. Immune program induction in matched patient-derived organoids correlated with the degree of MAPK inhibition. These data suggest a potential tumor cell-intrinsic mechanism of cooperativity between MAPK inhibition and immune response, warranting further clinical evaluation of optimized targeted and immune combinations in CRC. ClinicalTrials.gov registration: NCT03668431.
引用
- Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med. 2023. PMID: 36702949. doi:10.1038/s41591-022-02181-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。